Teva Pharmaceutical Industries Ltd. (TEVA)

7.50
0.27 3.47
NYSE : Health Technology
Prev Close 7.77
Open 7.66
Day Low/High 7.41 / 7.88
52 Wk Low/High 6.07 / 23.97
Volume 20.38M
Avg Volume 20.58M
Exchange NYSE
Shares Outstanding 1.09B
Market Cap 7.77B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
Warren Buffett Stocks Fall: Teva Pharmaceutical Up 1.8%; StoneCo Off 3.7%

Warren Buffett Stocks Fall: Teva Pharmaceutical Up 1.8%; StoneCo Off 3.7%

Gainers trail losers in Warren Buffett's Berkshire portfolio.

TEVA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Teva Pharmaceutical Industries Limited To Contact The Firm

TEVA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Teva Pharmaceutical Industries Limited To Contact The Firm

NEW YORK, May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Teva Pharmaceuticals Industries Limited ("Teva" or the "Company") (NYSE:TEVA).

Dow Ends Sharply Lower; Trade War Escalation Slams Stocks

Dow Ends Sharply Lower; Trade War Escalation Slams Stocks

China's retaliatory tariffs spark biggest selloff on Wall Street since January.

How Low Can Teva Pharmaceutical Stock Go? Don't Fight the Tape

How Low Can Teva Pharmaceutical Stock Go? Don't Fight the Tape

Do not try to pick a bottom on this stock.

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

Endo Pharmaceutical Falls After Downgrade to Underweight at JPMorgan

Endo Pharmaceutical Falls After Downgrade to Underweight at JPMorgan

Endo Pharmaceutical is downgraded to underweight from neutral at JPMorgan.

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.

Teva Announces The Launch Of A Generic Version Of Delzicol® (mesalamine) Delayed-Release Capsules In The United States

Teva Announces The Launch Of A Generic Version Of Delzicol® (mesalamine) Delayed-Release Capsules In The United States

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of Delzicol ®1 (mesalamine) delayed-release capsules, 400 mg, in the U.

Teva Announces Launch Of A Generic Version Of Tarceva® (erlotinib) Tablets In The United States

Teva Announces Launch Of A Generic Version Of Tarceva® (erlotinib) Tablets In The United States

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of Tarceva ®1 (erlotinib) tablets, 100 and 150 mg, in the U.

Teva To Present New Long-Term Data On Efficacy And Safety Of Fremanezumab At 2019 American Academy Of Neurology Annual Meeting

Teva To Present New Long-Term Data On Efficacy And Safety Of Fremanezumab At 2019 American Academy Of Neurology Annual Meeting

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced results from new long-term analyses of the efficacy and safety of fremanezumab, being presented at the 71 st Annual Meeting of the American Academy of Neurology (AAN) in...

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?

Teva Reports First Quarter 2019 Financial Results

Teva Reports First Quarter 2019 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2019.

Teva Announces Launch Of A Generic Version Of Letairis® (ambrisentan) Tablets In The United States

Teva Announces Launch Of A Generic Version Of Letairis® (ambrisentan) Tablets In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Letairis ®1 (ambrisentan) Tablets, 5 mg and 10 mg, in the U.

Teva To Present New Central Nervous System Portfolio Data At 71st Annual Meeting Of The American Academy Of Neurology

Teva To Present New Central Nervous System Portfolio Data At 71st Annual Meeting Of The American Academy Of Neurology

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Company will present data at the 71 st Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia from May 4-10, 2019.

New Highs Washing Away

Lack of new highs and abundance of new lows make task of finding stocks to go long on harder.

Teva Announces Update On Fremanezumab Clinical Development For Use In Episodic Cluster Headache

Teva Announces Update On Fremanezumab Clinical Development For Use In Episodic Cluster Headache

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches.

Teva Announces Launch Of A Generic Version Of VESIcare® (solifenacin Succinate) Tablets In The United States

Teva Announces Launch Of A Generic Version Of VESIcare® (solifenacin Succinate) Tablets In The United States

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare ®1 (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.

Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new $2.

Teva To Host Conference Call To Discuss First Quarter 2019 Financial Results At 8 A.m. ET On May 2, 2019

Teva To Host Conference Call To Discuss First Quarter 2019 Financial Results At 8 A.m. ET On May 2, 2019

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter 2019 financial results on Thursday, May 2, 2019 at 7:00 a.

Weekly Roundup

Markets pushed higher as we gear up for first-quarter results starting next week.

AJOVY Capshot (Graphic: Business Wire)

AJOVY Capshot (Graphic: Business Wire)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the European Commission (EC) has granted the Marketing Authorization for AJOVY (fremanezumab) 225 mg solution for injection in pre-filled syringe for the prophylaxis of...

Teva's COPAXONE® 40mg - Favorable Response From European Patent Office

Teva's COPAXONE® 40mg - Favorable Response From European Patent Office

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office's (EPO) Opposition Division upheld patent EP 2 949 335 covering Teva's COPAXONE ® 40mg product in Europe.

More Mud on Johnson & Johnson?

More Mud on Johnson & Johnson?

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.

Teva Pharmaceutical Initiated at Market Perform at BMO

Teva Pharmaceutical Initiated at Market Perform at BMO

Coverage of Teva Pharmaceutical is initiated at market perform at BMO with a price target of $18.

OxyContin Maker Purdue Pharma Agrees to $270 Million Settlement With Oklahoma

OxyContin Maker Purdue Pharma Agrees to $270 Million Settlement With Oklahoma

Most of the settlement money reportedly will go to funding a new center for research, education and treatment of addiction and pain at Oklahoma State University.

Teva Announces Launch Of A Generic Version Of EXJADE® (deferasirox) Tablets For Oral Suspension In The United States

Teva Announces Launch Of A Generic Version Of EXJADE® (deferasirox) Tablets For Oral Suspension In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE ®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Market Direction, Big Anniversary and a GE Play: Market Recon

Market Direction, Big Anniversary and a GE Play: Market Recon

There is still no news on China trade, so keep your chinstrap buckled and wear your flak jacket.

Teva Announces Launch Of An Authorized Generic Of Flector® Patch (diclofenac Epolamine Topical Patch) In The United States

Teva Announces Launch Of An Authorized Generic Of Flector® Patch (diclofenac Epolamine Topical Patch) In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Flector ®1 Patch, 1.

Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission

Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission

Teva Pharmaceuticals shares were indicated lower in pre-market trading Wednesday after the drugmaker reached a settlement with the Federal Trade Commission over allegations it delayed the release of generic medicines through agreements with pharmaceutical rivals.

TheStreet Quant Rating: D (Sell)